Chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center
Professor, Weill-Cornell Medical College, New York
Dr. Anas Younes is chief of Memorial Sloan Kettering’s Lymphoma Service, Division of Hematologic Oncology, where he is responsible for continuing to accelerate the translation of scientific discoveries into novel treatment strategies to improve the cure rate and survival of patients with Hodgkin (HL) and non-Hodgkin lymphoma (NHL). His interests include HL, NHL, developing novel targeted therapies for lymphoma, identification of biomarkers for treatment, and participation in clinical trials. He led the trials that resulted in the FDA approval of brentuximab vedotin and nivolumab for the treatment of patients with relapsed Hodgkin lymphoma. Dr. Younes has published more than 250 papers, and serves on the Scientific Advisory Board of the Lymphoma Research Foundation. He is a past member of the National Cancer Institute Lymphoma Steering Committee. He has served as the principal investigator of more than 60 clinical trials and has led the National Cancer Institute-funded SPORE (Specialized Programs of Research Excellence) in lymphoma both at M.D. Anderson Cancer Center, and most recently at MSKCC. He is also the principal investigator of a SCOR grant supported by the Leukaemia and Lymphoma Society.